Videos
Real-World Study on Niraparib as First Line Maintenance for Newly Diagnosed Advanced Ovarian Cancer
05/03/2022
Jinan Liu, MD, PhD, GlaxoSmithKline, Upper Providence, PA, evaluated dose assignment and uptake of the individualized starting dose among US patients with ovarian cancer who were receiving niraparib, the only poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor that is approved by the Food and Drug Administration, as first-line maintenance therapy.
Liu J, et al. Starting dose of niraparib as first-line maintenance among patients with newly diagnosed advanced ovarian cancer in a real-world database. Presented at: the 2022 SGO Annual Meeting on Women’s Cancer; March 18-21, 2022. Poster 352. Dr Liu reports no disclosures.
Current Issue
October 2024
Volume 10
Issue 5
Subscribe
Journal of Clinical Pathways Newsletter